Article Versions Notes

Hellmold D, Kubelt C, Daunke T, Beckinger S, Janssen O, Hauck M, Schütt F, Adelung R, Lucius R, Haag J, et al. Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells. International Journal of Molecular Sciences. 2023; 24(10):9075. https://doi.org/10.3390/ijms24109075

Hellmold, Dana, Carolin Kubelt, Tina Daunke, Silje Beckinger, Ottmar Janssen, Margarethe Hauck, Fabian Schütt, Rainer Adelung, Ralph Lucius, Jochen Haag, and et al. 2023. "Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells" International Journal of Molecular Sciences 24, no. 10: 9075. https://doi.org/10.3390/ijms24109075

Hellmold, D., Kubelt, C., Daunke, T., Beckinger, S., Janssen, O., Hauck, M., Schütt, F., Adelung, R., Lucius, R., Haag, J., Sebens, S., Synowitz, M., & Held-Feindt, J. (2023). Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells. International Journal of Molecular Sciences, 24(10), 9075. https://doi.org/10.3390/ijms24109075